← Leaderboards
Shirit Einav
Stanford University
$7,596,823
Attributed
$7,596,823
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $779.4K · FY2008–25$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,596,823 · 3
By mechanism
R01$3,659,295 · 1
U19$3,284,533 · 1
K08$652,995 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Emmanuel J Mignot$26,217,198
- Scott Dexter Boyd$18,651,021
- Robert S Negrin$29,816,136
- Hannah A Valantine$0
- Hanlee Ji$24,780,644
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadMolecularIn VivoResistanceRna VirusesMolecular VirologyPharmaceutical PreparationsVirusCombatAntiviral AgentsInhibitor/AntagonistGeneticDesignViralAntineoplastic AgentsIntegration Host FactorsLightBiochemicalInfectionPathway InteractionsMediatingGenomicsMembraneData Set
Grant awards (15)
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections$717,555
R01 · FY2025 · AI · contact PI
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections$726,503
R01 · FY2024 · AI · contact PI
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections$713,845
R01 · FY2023 · AI · contact PI
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections$721,967
R01 · FY2022 · AI · contact PI
Advancing the development of a novel class of small molecules for treating pan-coronavirus infections$779,425
R01 · FY2021 · AI · contact PI
Accelerating novel countermeasures against RNA viruses through repurposing$668,817
U19 · FY2018 · AI · contact PI
Accelerating novel countermeasures against RNA viruses through repurposing$665,382
U19 · FY2017 · AI · contact PI
Accelerating novel countermeasures against RNA viruses through repurposing$658,172
U19 · FY2016 · AI · contact PI
Accelerating novel countermeasures against RNA viruses through repurposing$655,625
U19 · FY2015 · AI · contact PI
Accelerating novel countermeasures against RNA viruses through repurposing$636,537
U19 · FY2014 · AI · contact PI
Novel antviral targets in Hepatitis C virus NS4B protein$130,599
K08 · FY2012 · AI · contact PI
Novel antviral targets in Hepatitis C virus NS4B protein$130,599
K08 · FY2011 · AI · contact PI
Novel antviral targets in Hepatitis C virus NS4B protein$130,599
K08 · FY2010 · AI · contact PI
Novel antviral targets in Hepatitis C virus NS4B protein$130,599
K08 · FY2009 · AI · contact PI
Novel antviral targets in Hepatitis C virus NS4B protein$130,599
K08 · FY2008 · AI · contact PI